Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

The drug, Alyftrek, works by regulating the flow of water and salt in and out of organs in CF patients, improving their overall function. It helps fix a faulty protein (CFTR) in their cells ...

Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

While in the near term, expansion to younger age groups should continue to drive CF sales growth, the launch of Alyftrek should drive growth in the medium term. The approval of Vertex and partner ...

The Gairdner Foundation is pleased to announce the 2025 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical and global health research and discoveries.

With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations ...